Payal Kohli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Payal Kohli has a total of 192 co-authors. Here are the top co-authors by number of shared publications:
Christopher P. Cannon
TIMI Study Group Division of Cardiology, Department of Medicine and Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts
5 shared publications- Robert Patrick Giugliano
TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
5 shared publications - Christopher P. Cannon
TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA 02115, USA
4 shared publications Ransi Somaratne
Amgen, Inc., Thousand Oaks, California
4 shared publicationsRoger S. Blumenthal
Department of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
4 shared publications- Roger S. Blumenthal
Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University, Baltimore, MD, USA
4 shared publications
Latest Publications
- Open Access
- 21 March 2025
- Published by Radcliffe Medical Media Ltd in US Cardiology Review
- Vol. 19, e06
High-sensitivity C-reactive Protein in Atherosclerotic Cardiovascular Disease: To Measure or Not to Measure?
Inflammation and dyslipidemia are central to the pathogenesis of atherosclerotic cardiovascular disease (ASCVD). While lipid-lowering therapies are the cornerstone of ASCVD prevention and treatment, there are other emerging targets, including inflammation (which has been dubbed the ‘residual inflammatory risk’), that can be addressed after LDL cholesterol thresholds have been reached. Research over the past 20 years has identified C-reactive protein (CRP) as a key marker of inflammation with atherosclerosis. The association of more sensitive measures of CRP (high-sensitivity C-reactive protein [hsCRP]) with ASCVD risk in epidemiological studies has also led to its incorporation as a risk enhancer in primary prevention guidelines and its incorporation into risk stratification tools. While there are no formal recommendations related to measurement of hsCRP in secondary prevention, consideration should be given to an individualized approach that addresses inflammatory risk in those with major adverse cardiovascular events, despite maximal lipid-lowering therapy and well-controlled LDL cholesterol levels. The aim of this review is to discuss the role of inflammation in ASCVD, the use of hsCRP as a tool to assess residual inflammatory risk to target upstream pathways such as glucose intolerance and obesity, and to consider use of additional anti-inflammatory medications for ASCVD risk reduction. The authors provide clinical context around when to measure hsCRP in clinical practice and how to address residual inflammatory risk in ASCVD.
- 21 March 2025
- Published by Radcliffe Medical Media Ltd in US Cardiology Review
- Vol. 19, e06
Open AccessHigh-sensitivity C-reactive Protein in Atherosclerotic Cardiovascular Disease: To Measure or Not to Measure?
Inflammation and dyslipidemia are central to the pathogenesis of atherosclerotic cardiovascular disease (ASCVD). While lipid-lowering therapies are the cornerstone of ASCVD prevention and treatment, there are other emerging targets, including inflammation (which has been dubbed the ‘residual inflammatory risk’), that can be addressed after LDL cholesterol thresholds have been reached. Research over the past 20 years has identified C-reactive protein (CRP) as a key marker of inflammation with atherosclerosis. The association of more sensitive measures of CRP (high-sensitivity C-reactive protein [hsCRP]) with ASCVD risk in epidemiological studies has also led to its incorporation as a risk enhancer in primary prevention guidelines and its incorporation into risk stratification tools. While there are no formal recommendations related to measurement of hsCRP in secondary prevention, consideration should be given to an individualized approach that addresses inflammatory risk in those with major adverse cardiovascular events, despite maximal lipid-lowering therapy and well-controlled LDL cholesterol levels. The aim of this review is to discuss the role of inflammation in ASCVD, the use of hsCRP as a tool to assess residual inflammatory risk to target upstream pathways such as glucose intolerance and obesity, and to consider use of additional anti-inflammatory medications for ASCVD risk reduction. The authors provide clinical context around when to measure hsCRP in clinical practice and how to address residual inflammatory risk in ASCVD.
- Open Access
- 18 June 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (12) , e034053
New Perspectives in Management of Cardiovascular Risk Among People With Diabetes
Following the publication of results from multiple landmark cardiovascular outcome trials of antihyperglycemic medications over the past 8 years, there has been a major shift in the focus of care for people with type 2 diabetes, from control of hyperglycemia to managing cardiovascular risk. Multiple international cardiology and diabetes society guidelines and recommendations now endorse sodium‐glucose cotransporter‐2 inhibitors and glucagon‐like protein‐1 receptor agonists as first‐line therapies to mitigate cardiovascular risk. The most recent publication is the 2023 European Society of Cardiology guideline on the management of cardiovascular disease in those with type 2 diabetes that, for the first time, recommends use of both classes of medications for the mitigation of cardiovascular risk for those with or at high risk for atherosclerotic cardiovascular disease, heart failure, and chronic kidney disease. Here, we review the evidence behind contemporary society guidelines and recommendations for the management of type 2 diabetes and cardiovascular risk.
- 18 June 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (12) , e034053
Open AccessNew Perspectives in Management of Cardiovascular Risk Among People With Diabetes
Following the publication of results from multiple landmark cardiovascular outcome trials of antihyperglycemic medications over the past 8 years, there has been a major shift in the focus of care for people with type 2 diabetes, from control of hyperglycemia to managing cardiovascular risk. Multiple international cardiology and diabetes society guidelines and recommendations now endorse sodium‐glucose cotransporter‐2 inhibitors and glucagon‐like protein‐1 receptor agonists as first‐line therapies to mitigate cardiovascular risk. The most recent publication is the 2023 European Society of Cardiology guideline on the management of cardiovascular disease in those with type 2 diabetes that, for the first time, recommends use of both classes of medications for the mitigation of cardiovascular risk for those with or at high risk for atherosclerotic cardiovascular disease, heart failure, and chronic kidney disease. Here, we review the evidence behind contemporary society guidelines and recommendations for the management of type 2 diabetes and cardiovascular risk.
- 1 April 2024
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 17 (4) , e010763
PREVENT Equations: A New Era in Cardiovascular Disease Risk Assessment
- 1 April 2024
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 17 (4) , e010763
PREVENT Equations: A New Era in Cardiovascular Disease Risk Assessment
- Top Cited PapersOpen Access
- 18 March 2024
- Published by Elsevier in American Journal of Preventive Cardiology
- Vol. 18, 100649
The importance of LDL-C lowering in atherosclerotic cardiovascular disease prevention: Lower for longer is better
- 18 March 2024
- Published by Elsevier in American Journal of Preventive Cardiology
- Vol. 18, 100649
Top Cited PapersOpen AccessThe importance of LDL-C lowering in atherosclerotic cardiovascular disease prevention: Lower for longer is better
- 22 October 2023
- Published by Elsevier in The American Journal of Medicine
- Vol. 137 (2) , 85-91
Applying the ABCs of Cardiovascular Disease Prevention to the 2023 AHA/ACC Multisociety Chronic Coronary Disease Guidelines
- 22 October 2023
- Published by Elsevier in The American Journal of Medicine
- Vol. 137 (2) , 85-91
Applying the ABCs of Cardiovascular Disease Prevention to the 2023 AHA/ACC Multisociety Chronic Coronary Disease Guidelines
- 7 May 2022
- Published by Springer Nature in Current Cardiology Reports
- Vol. 24 (7) , 829-837
COVID’s Impact on Non-communicable Diseases: What We Do Not Know May Hurt Us
Purpose of Review In this review, we outline the impacts of the COVID-19 pandemic on non-communicable diseases around the world. Recent Findings The mechanisms of COVID-19’s impact on non-communicable diseases are both direct and indirect. The direct mechanisms include direct vascular and myocardial injury as well as pancreatic injury increasing incidence of new-onset diabetes. Indirect effects of the pandemic on non-communicable disease include delayed presentation for acute illness including STEMI and the impact of social distancing and quarantine policies on socialization, mental health, physical activity, and the downstream health impacts of inactivity and deconditioning. Summary International focus has been on disease variants, infection control and management, healthcare system, and resource utilization and infection incidence. However, the impact of this pandemic on non-communicable diseases has been largely overlooked but will manifest itself in the coming years to decades.
- 7 May 2022
- Published by Springer Nature in Current Cardiology Reports
- Vol. 24 (7) , 829-837
COVID’s Impact on Non-communicable Diseases: What We Do Not Know May Hurt Us
Purpose of Review In this review, we outline the impacts of the COVID-19 pandemic on non-communicable diseases around the world. Recent Findings The mechanisms of COVID-19’s impact on non-communicable diseases are both direct and indirect. The direct mechanisms include direct vascular and myocardial injury as well as pancreatic injury increasing incidence of new-onset diabetes. Indirect effects of the pandemic on non-communicable disease include delayed presentation for acute illness including STEMI and the impact of social distancing and quarantine policies on socialization, mental health, physical activity, and the downstream health impacts of inactivity and deconditioning. Summary International focus has been on disease variants, infection control and management, healthcare system, and resource utilization and infection incidence. However, the impact of this pandemic on non-communicable diseases has been largely overlooked but will manifest itself in the coming years to decades.
- Open Access
- 14 July 2020
- Published by Wolters Kluwer Health in Circulation
- Vol. 142 (2) , 98-100
Surfing the Waves of the COVID-19 Pandemic as a Cardiovascular Clinician
- 14 July 2020
- Published by Wolters Kluwer Health in Circulation
- Vol. 142 (2) , 98-100
Open AccessSurfing the Waves of the COVID-19 Pandemic as a Cardiovascular Clinician
- 31 October 2019
- Published by Springer Nature in Current Atherosclerosis Reports
- Vol. 21 (11) , 43
Popular Media and Cardiovascular Medicine: “with Great Power There Must Also Come Great Responsibility”
Media sources, such as the Internet, television, and social media, have become powerful communication tools that have transformed the way medical information is acquired across the world.
- 31 October 2019
- Published by Springer Nature in Current Atherosclerosis Reports
- Vol. 21 (11) , 43
Popular Media and Cardiovascular Medicine: “with Great Power There Must Also Come Great Responsibility”
Media sources, such as the Internet, television, and social media, have become powerful communication tools that have transformed the way medical information is acquired across the world.
- 10 January 2019
- Published by Springer Nature in Current Atherosclerosis Reports
- Vol. 21 (1) , 1-7
Omega-3 Fatty Acid and Cardiovascular Outcomes: Insights From Recent Clinical Trials
Purpose of Review Omega-3 fatty acids (ω-3 FA) are among the most well-recognized health supplements but their cardiovascular benefits have long been controversial owing to inconsistent results from previous cardiovascular outcomes trials (CVOT). In this article, we provide a short review of existing literature followed by recent randomized clinical trial data, with a discussion of the potential clinical implications of these new findings. Recent Findings Data from the randomized, controlled trial REDUCE-IT, when viewed within the context of other recently published trials ASCEND and VITAL, add to a growing body of evidence on the use of ω-3 FA therapies in the treatment of atherosclerotic cardiovascular disease (ASCVD). Summary Given the different formulations, dosages, and patient populations studied, CVOTs of ω-3 FA have provided valuable insight into the use of these agents in cardioprotection. Current data suggest that higher dosages of pure eicosapentaenoic acid ω-3 FA formulations provide additional benefit in reduction of ASCVD events.
- 10 January 2019
- Published by Springer Nature in Current Atherosclerosis Reports
- Vol. 21 (1) , 1-7
Omega-3 Fatty Acid and Cardiovascular Outcomes: Insights From Recent Clinical Trials
Purpose of Review Omega-3 fatty acids (ω-3 FA) are among the most well-recognized health supplements but their cardiovascular benefits have long been controversial owing to inconsistent results from previous cardiovascular outcomes trials (CVOT). In this article, we provide a short review of existing literature followed by recent randomized clinical trial data, with a discussion of the potential clinical implications of these new findings. Recent Findings Data from the randomized, controlled trial REDUCE-IT, when viewed within the context of other recently published trials ASCEND and VITAL, add to a growing body of evidence on the use of ω-3 FA therapies in the treatment of atherosclerotic cardiovascular disease (ASCVD). Summary Given the different formulations, dosages, and patient populations studied, CVOTs of ω-3 FA have provided valuable insight into the use of these agents in cardioprotection. Current data suggest that higher dosages of pure eicosapentaenoic acid ω-3 FA formulations provide additional benefit in reduction of ASCVD events.